We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Multiple Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of ACHN-975 in Healthy Volunteers

This study has been terminated.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01870245
First Posted: June 6, 2013
Last Update Posted: July 1, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
Achaogen, Inc.
  Purpose
This is a randomized, double-blind, placebo-controlled, multiple-dose study, designed to assess the safety, tolerability, and pharmacokinetics (PK) of ACHN-975. This study will take place in the US at one clinical site.

Condition Intervention Phase
Healthy Volunteer Drug: ACHN-975 Drug: placebo Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase 1 Multiple Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of ACHN-975 Administered Intravenously to Healthy Volunteers

Further study details as provided by Achaogen, Inc.:

Primary Outcome Measures:
  • Frequency of AEs [ Time Frame: 28 days ]
  • Severity of AEs [ Time Frame: 28 days ]

Secondary Outcome Measures:
  • Plasma concentrations of ACHN-975 [ Time Frame: 16 days ]

Enrollment: 4
Study Start Date: May 2013
Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: ACHN-975 Drug: ACHN-975
Intravenous multiple dose
Placebo Comparator: Placebo Drug: placebo
Intravenous multiple dose

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Key Inclusion Criteria:

  • Body weight between 40 and 100 kilograms (between ~88 pounds and ~220 pounds)
  • Use of contraception
  • Stable health
  • Negative tests for alcohol, tobacco, and drugs of abuse

Key Exclusion Criteria:

  • History of clinically significant disease
  • Pregnancy
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01870245


Locations
United States, Kansas
Investigational Site
Overland Park, Kansas, United States, 66211
Sponsors and Collaborators
Achaogen, Inc.
Investigators
Study Director: Medical Director Achaogen, Inc.
  More Information

Responsible Party: Achaogen, Inc.
ClinicalTrials.gov Identifier: NCT01870245     History of Changes
Other Study ID Numbers: ACHN-975-002
First Submitted: May 29, 2013
First Posted: June 6, 2013
Last Update Posted: July 1, 2013
Last Verified: June 2013